A Combination of Savolitinib and Osimertinib Prolongs PFS in Patients with EGFR-mutated NSCLC and Acquired MET Amplification After Progression On a First-Line EGFR TKI By Ogkologos - January 16, 2026 459 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SACHI study Source RELATED ARTICLESMORE FROM AUTHOR Tambotatug Pelitecan Leads to Better Clinical Outcomes than Topotecan Among Patients with Relapsed SCLC After Platinum-based Therapy ESMO Welcomes European Parliament Calls to Strengthen and Protect Europe’s Cancer Workforce No improvement in OS, but more grade 3 or higher AEs with atezolizumab plus SBRT among patients with inoperable early-stage NSCLC MOST POPULAR Approval Expanded for Venetoclax in Chronic Lymphocytic Leukemia June 22, 2018 Foodie Friday: What to do with all these zucchini? July 9, 2021 Selpercatinib Slows Progression of RET-Positive Lung, Medullary Thyroid Cancers November 15, 2023 Peptide Receptor Radionuclide Therapy [177Lu]Lu-Edotreotide Prolongs PFS in Patients with Advanced,... July 28, 2026 Load more HOT NEWS Wales: 4 in 10 with possible cancer symptoms didn’t contact GP EMA Recommends Granting a Conditional Marketing Authorisation for Idecabtagene Vicleucel Study Shows Supplements Increase Risk of Relapse and Death in Breast... El cáncer en mi comunidad: Ampliar el acceso a las pruebas...
